Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in rheumatic disease-associated fibrotic interstitial lung disease
NL-OMON59070Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nerandomilast in connective tissue disease-associated interstitial lung disease (CTD-ILD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Absolute change from baseline in QILD score on HRCT at Week 26. Started Dec 2025; status: active, not recruiting.
02
Drugs
nerandomilast
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on NL-OMON59070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59070.